Saturday, May 30, 2020 9:47:48 PM
Translation. not everyone is comfortable to venture into the unknown even though research strongly indicates it should be safe and rewarding.
The captain, James Holvis has brought a sport drink line to market.
The first officer Larry Kubin brings ties to the NFL, 2019 key note speaker of the Center for Brain Injury Research and Repair of Penn Medicine conference. and a strong financial background with 32 years as Managing Director for Donnelley Financial Solutions.
Science office Michael Fountain holds 30 issued United States patents and over 100 international patents. These patented technology platforms are currently utilized in over 180 products.
The chief engineer, the University of Pennsylvania has been and continues with their technology along with NDT Pharm technology to develop the drug delivery technology that crosses the blood brain barrier.
The crew is rounded out with
Edward Mathias a Senior Advisor with The Carlyle Group and holds an M.B.A. from the Harvard Business School and an undergraduate degree from the University of Pennsylvania where he currently serves as a Trustee Emeritus. He is a member of the President’s Advisory Council on Doing Business in Africa, The Council on Foreign Relations, and The Trustees' Council at The National Gallery of Art.
And
Stuart Yarbrough Director of Cision with professional experience includes over 24 years in public accounting, primarily with Ernst & Young and BDO Seidman, LLP. Since June 2008, Mr. Yarbrough has been a private investor. From February 2007 through its final distributions during June 2008, Mr. Yarbrough served as the chief executive officer of 3Point Capital Partners, a private equity firm. From 1994 through February 2007, Mr. Yarbrough was a principal at CrossHill Financial Group Inc., a company he co-founded, which provided investment banking services and venture debt financing to growth companies. Mr. Yarbrough previously served on the board of directors of Solera Holdings, Inc. and DigitalNet Holdings, Inc., as well as several other public companies.
The ship powered by the Nano Particle Complex.
ENGAGE!
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM